Advertisement
Advertisement
PCRX
Pacira BioSciences, Inc. Common Stock
23.15
USDSponsored
-0.49
-2.07%
May 08, 16:00 UTC -4
Closed
After-Market
23.18
+0.04
+0.15%
PCRX Earnings Reports
Positive Surprise Ratio
PCRX beat 27 of 42 last estimates.
64%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$193.74M
/$0.68
Implied change from Q1 26 (Revenue/ EPS)
+9.22%
/+13.33%
Implied change from Q2 25 (Revenue/ EPS)
+6.98%
/-8.11%
Pacira BioSciences, Inc. Common Stock earnings per share and revenue
On Apr 30, 2026, PCRX reported earnings of 0.60 USD per share (EPS) for Q1 26, beating the estimate of 0.57 USD, resulting in a 4.42% surprise. Revenue reached 177.38 million, compared to an expected 176.79 million, with a 0.33% difference. The market reacted with a -4.12% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of 0.68 USD, with revenue projected to reach 193.74 million USD, implying an increase of 13.33% EPS, and increase of 9.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Pacira BioSciences, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Pacira BioSciences, Inc. Common Stock reported EPS of $0.60, beating estimates by 4.42%, and revenue of $177.38M, 0.33% above expectations.
How did the market react to Pacira BioSciences, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -4.12%, changed from $25.49 before the earnings release to $24.44 the day after.
When is Pacira BioSciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Pacira BioSciences, Inc. Common Stock's next earnings report?
Based on 5
analysts, Pacira BioSciences, Inc. Common Stock is expected to report EPS of $0.68 and revenue of $193.74M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement